ANIX Anixa Biosciences

Anixa: Dr. Conejo-Garcia to keynote on ovarian cancer CAR-T at Midwest Focus Conference

Anixa Biosciences announced that the inventor of its ovarian cancer CAR-T therapy, Dr. Jose Conejo-Garcia, will deliver a keynote on immunotherapy for ovarian cancer at the Ovarian Cancer Midwest Focus Conference on November 2-3, 2026.

Anixa Reports First Stable Disease in Phase 1 Ovarian Cancer CAR-T Trial

The first patient in the fifth (highest) dose cohort of Anixa's Phase 1 FSHR-targeted CAR-T (lira-cel) trial showed stable disease at the 90-day assessment; no dose-limiting toxicities have been observed. Multiple patients have exceeded one year of survival, one beyond two years. This is the first reported response of stable disease in the study.

Anixa treats second patient in Cohort 5 of FSHR CAR-T ovarian cancer trial

Anixa dosed the second patient in the highest dose cohort (Cohort 5) of its Phase 1 ovarian cancer CAR-T trial. No dose-limiting toxicities observed to date; four patients have survived over one year (up to 28 months) in this heavily pre-treated population.

Anixa Biosciences Granted Australian Patent for Breast Cancer Vaccine Through 2040

IP Australia issued composition-of-matter patent 2020221280 exclusively licensed from Cleveland Clinic, providing protection for Anixa's α-lactalbumin breast cancer vaccine in Australia until 2040. This expands the company's global IP estate which already covers the US, Europe, China, and Japan. The patent supports continued clinical development and potential future regulatory approvals and partnerships.